Stanley Druckenmiller's XENE Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 238,600 shares of Xenon Pharmaceuticals Inc. (XENE) worth $13.88 M, representing 0.41% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in XENE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Xenon Pharmaceuticals (XENE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xenon Pharmaceuticals (XENE) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +238,600 | New Buy | 238,600 | $58.15 |
Stanley Druckenmiller's Xenon Pharmaceuticals Investment FAQs
Stanley Druckenmiller first purchased Xenon Pharmaceuticals Inc. (XENE) in Q1 2026, acquiring 238,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Xenon Pharmaceuticals Inc. (XENE) for 1 quarters since Q1 2026.
Stanley Druckenmiller's largest addition to Xenon Pharmaceuticals Inc. (XENE) was in Q1 2026, adding 238,600 shares worth $13.88 M.
According to the latest 13F filing for Q1 2026, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 238,600 shares of Xenon Pharmaceuticals Inc. (XENE), valued at approximately $13.88 M.
As of the Q1 2026 filing, Xenon Pharmaceuticals Inc. (XENE) represents approximately 0.41% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Xenon Pharmaceuticals Inc. (XENE) was 238,600 shares, as reported at the end of Q1 2026.